top of page

Ulcerative Colitis

​

​

  • Merck TL1A

      A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Induction and Maintenance Study to Evaluate the Efficacy and Safety of                PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis

      Study Details | A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active                  Ulcerative Colitis (MK-7240-001) | ClinicalTrials.gov

​

  • Lilly DSAG

      An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult                Patients with Moderately to Severely Active Ulcerative Colitis

      Study Details | A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis |                             ClinicalTrials.gov    

​​

       

Crohn's Disease

​​

  • Merck TL1A

       A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants With           Moderately to Severely Active Crohn's Disease

       Study Details | A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's                   Disease (MK-7240-008) | ClinicalTrials.gov

  • AstraZeneca

      A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe              Crohn’s Disease (AMALTHEA)

      Study Details | Phase IIa Study Evaluating AZD7798 in Crohn's Disease | ClinicalTrials.gov

  • Takeda  

      An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy with Vedolizumab Intravenous (IV) and                   Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn’s Disease (CD)

      Study Details | A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease |      ClinicalTrials.gov

​

​

​

​

​

​

​​

bottom of page